NCT01857895View on ClinicalTrials.gov

Feasibility Study of Exenatide by Continuous Subcutaneous Infusion

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

May 16, 2013

Primary Completion Date

November 1, 2013

Study Completion Date

November 1, 2013

Conditions

Obesity

Interventions

DRUG

Exenatide

Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT01857895 - Feasibility Study of Exenatide by Continuous Subcutaneous Infusion | Biotech Hunter | Biotech Hunter